New FDA Policy On Diagnostics Studies “Fills A Big Gap,” CDRH Chief Says
This article was originally published in The Gray Sheet
Executive SummaryCompanies specializing in diagnostic products should pay close attention to a new, statistics-focused guidance document from FDA, device center Director Dan Schultz says
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.